Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25548851 | 0.92 | FOLH1 (0.60) | NOD1FOLH1GLP1RALBGNPAT | |
| SCHEMBL29431224 | 0.88 | KMT2A (0.42) | NOD1GLP1R | |
| SCHEMBL14063682 | 0.85 | NOD1 (0.51) | NOD1FOLH1GLP1RALBGNPAT | |
| SCHEMBL13057101 | 0.85 | FOLH1 (0.55) | NOD1FOLH1GLP1RALBGNPAT | |
| SCHEMBL14063681 | 0.85 | NOD1 (0.53) | NOD1FOLH1GLP1RALBGNPAT | |
| SCHEMBL13674388 | 0.84 | GNPAT (0.64) | NOD1FOLH1GLP1RALBGNPAT | |
| SCHEMBL14063709 | 0.84 | TSHR (0.57) | NOD1FOLH1GLP1RALBEPHX2 | |
| SCHEMBL25542854 | 0.83 | FOLH1 (0.58) | NOD1FOLH1GLP1RALBEPHX2 | |
| SCHEMBL25542887 | 0.83 | ALB (0.58) | NOD1FOLH1GLP1RALBEPHX2 | |
| SCHEMBL7364390 | 0.83 | NOD1 (0.60) | NOD1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026037-A1 | ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-01-25 | — | — | US | claimed |
| EP-4247426-A2 | ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2023-09-27 | — | — | EP | claimed |
| WO-2022108976-A2 | ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-27 | — | — | WO | claimed |
| US-20240124889-A1 | COMPOSITIONS AND METHODS FOR THE VECTORED AUGMENTATION OF PROTEIN DESTRUCTION, EXPRESSION AND/OR REGULATION | VOYAGER THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117794568-A | anti-GPA 33 multispecific antibodies and uses thereof | 纪念斯隆凯特琳癌症中心 | 2024-03-29 | — | — | CN | disclosed |
| US-20240026037-A1 | ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4247426-A2 | ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20220389449-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE | VOYAGER THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022108976-A2 | ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11326182-B2 | Compositions for the treatment of disease | VOYAGER THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |